Jena, Germany, April 30, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will …
interessant könnte der einblick werden im Juni..
Discussions will address underlying development rationales and expected Phase IIa trial design and provide insights into the commercial opportunity